298 related articles for article (PubMed ID: 36822363)
21. Perioperative ctDNA-Based Molecular Residual Disease Detection for Non-Small Cell Lung Cancer: A Prospective Multicenter Cohort Study (LUNGCA-1).
Xia L; Mei J; Kang R; Deng S; Chen Y; Yang Y; Feng G; Deng Y; Gan F; Lin Y; Pu Q; Ma L; Lin F; Yuan Y; Hu Y; Guo C; Liao H; Liu C; Zhu Y; Wang W; Liu Z; Xu Y; Li K; Li C; Li Q; He J; Chen W; Zhang X; Kou Y; Wang Y; Wu Z; Che G; Chen L; Liu L
Clin Cancer Res; 2022 Aug; 28(15):3308-3317. PubMed ID: 34844976
[TBL] [Abstract][Full Text] [Related]
22. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
Chen Y
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
[TBL] [Abstract][Full Text] [Related]
23. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group.
Pascual J; Attard G; Bidard FC; Curigliano G; De Mattos-Arruda L; Diehn M; Italiano A; Lindberg J; Merker JD; Montagut C; Normanno N; Pantel K; Pentheroudakis G; Popat S; Reis-Filho JS; Tie J; Seoane J; Tarazona N; Yoshino T; Turner NC
Ann Oncol; 2022 Aug; 33(8):750-768. PubMed ID: 35809752
[TBL] [Abstract][Full Text] [Related]
24. Tumor-agnostic plasma assay for circulating tumor DNA detects minimal residual disease and predicts outcome in locally advanced squamous cell carcinoma of the head and neck.
Honoré N; van Marcke C; Galot R; Helaers R; Ambroise J; van Maanen A; Mendola A; Dahou H; Marbaix E; Van Eeckhout P; Longton E; Magremanne M; Schmitz S; Limaye N; Machiels JP
Ann Oncol; 2023 Dec; 34(12):1175-1186. PubMed ID: 37879442
[TBL] [Abstract][Full Text] [Related]
25. Detection of Minimal Residual Disease Using ctDNA in Lung Cancer: Current Evidence and Future Directions.
Chae YK; Oh MS
J Thorac Oncol; 2019 Jan; 14(1):16-24. PubMed ID: 30296486
[TBL] [Abstract][Full Text] [Related]
26. Circulating Tumor DNA Minimal Residual Disease Detection of Non-Small-Cell Lung Cancer Treated With Curative Intent.
Pellini B; Chaudhuri AA
J Clin Oncol; 2022 Feb; 40(6):567-575. PubMed ID: 34985936
[TBL] [Abstract][Full Text] [Related]
27. Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence.
Coombes RC; Page K; Salari R; Hastings RK; Armstrong A; Ahmed S; Ali S; Cleator S; Kenny L; Stebbing J; Rutherford M; Sethi H; Boydell A; Swenerton R; Fernandez-Garcia D; Gleason KLT; Goddard K; Guttery DS; Assaf ZJ; Wu HT; Natarajan P; Moore DA; Primrose L; Dashner S; Tin AS; Balcioglu M; Srinivasan R; Shchegrova SV; Olson A; Hafez D; Billings P; Aleshin A; Rehman F; Toghill BJ; Hills A; Louie MC; Lin CJ; Zimmermann BG; Shaw JA
Clin Cancer Res; 2019 Jul; 25(14):4255-4263. PubMed ID: 30992300
[TBL] [Abstract][Full Text] [Related]
28. Circulating tumor DNA-based molecular residual disease detection for treatment monitoring in advanced melanoma patients.
Eroglu Z; Krinshpun S; Kalashnikova E; Sudhaman S; Ozturk Topcu T; Nichols M; Martin J; Bui KM; Palsuledesai CC; Malhotra M; Olshan P; Markowitz J; Khushalani NI; Tarhini AA; Messina JL; Aleshin A
Cancer; 2023 Jun; 129(11):1723-1734. PubMed ID: 36869646
[TBL] [Abstract][Full Text] [Related]
29. Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices.
Malla M; Loree JM; Kasi PM; Parikh AR
J Clin Oncol; 2022 Aug; 40(24):2846-2857. PubMed ID: 35839443
[TBL] [Abstract][Full Text] [Related]
30. Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.
Wang B; Pei J; Wang S; Cheng K; Yu J; Liu J
Crit Rev Oncol Hematol; 2022 Sep; 177():103771. PubMed ID: 35905822
[TBL] [Abstract][Full Text] [Related]
31. The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
Lee MS; Kaseb AO; Pant S
Clin Cancer Res; 2023 Sep; 29(17):3267-3274. PubMed ID: 37092904
[TBL] [Abstract][Full Text] [Related]
32. Longitudinal Monitoring of Circulating Tumor DNA From Plasma in Patients With Curative Resected Stages I to IIIA EGFR-Mutant Non-Small Cell Lung Cancer.
Jung HA; Ku BM; Kim YJ; Park S; Sun JM; Lee SH; Ahn JS; Cho JH; Kim HK; Choi YS; Choi YL; Shin SH; Jeong BH; Um SW; Kim H; Kim K; Ahn MJ; Kim J
J Thorac Oncol; 2023 Sep; 18(9):1199-1208. PubMed ID: 37308037
[TBL] [Abstract][Full Text] [Related]
33. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
34. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
Chen H; Zhou Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
[TBL] [Abstract][Full Text] [Related]
35. Postoperative circulating tumor DNA can refine risk stratification in resectable lung cancer: results from a multicenter study.
Fu R; Huang J; Tian X; Liang C; Xiong Y; Zhang JT; Jiang B; Dong S; Gong Y; Gao W; Li F; Shi Y; Liu Z; Gao X; Chen R; Zhong W; Zhang Y
Mol Oncol; 2023 May; 17(5):825-838. PubMed ID: 36732646
[TBL] [Abstract][Full Text] [Related]
36. Utilizing circulating tumour DNA in radiation oncology.
Rostami A; Bratman SV
Radiother Oncol; 2017 Sep; 124(3):357-364. PubMed ID: 28735685
[TBL] [Abstract][Full Text] [Related]
37. Emerging Roles of Circulating Tumor DNA for Increased Precision and Personalization in Radiation Oncology.
Earland N; Chen K; Semenkovich NP; Chauhan PS; Zevallos JP; Chaudhuri AA
Semin Radiat Oncol; 2023 Jul; 33(3):262-278. PubMed ID: 37331781
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
[TBL] [Abstract][Full Text] [Related]
39. Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
Tie J; Wang Y; Cohen J; Li L; Hong W; Christie M; Wong HL; Kosmider S; Wong R; Thomson B; Choi J; Fox A; Field K; Burge M; Shannon J; Kotasek D; Tebbutt NC; Karapetis C; Underhill C; Haydon A; Schaeffer J; Ptak J; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
PLoS Med; 2021 May; 18(5):e1003620. PubMed ID: 33939694
[TBL] [Abstract][Full Text] [Related]
40. Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences.
Henriksen TV; Tarazona N; Frydendahl A; Reinert T; Gimeno-Valiente F; Carbonell-Asins JA; Sharma S; Renner D; Hafez D; Roda D; Huerta M; Roselló S; Madsen AH; Løve US; Andersen PV; Thorlacius-Ussing O; Iversen LH; Gotschalck KA; Sethi H; Aleshin A; Cervantes A; Andersen CL
Clin Cancer Res; 2022 Feb; 28(3):507-517. PubMed ID: 34625408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]